Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) shares saw unusually-strong trading volume on Monday . Approximately 1,626,927 shares traded hands during trading, an increase of 302% from the previous session’s volume of 405,070 shares.The stock last traded at $4.05 and had previously closed at $3.50.

The stock’s market cap is $249.03 million. The firm has a 50 day moving average of $3.49 and a 200 day moving average of $4.39.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.48. The firm earned $8.10 million during the quarter, compared to the consensus estimate of $9.70 million. The firm’s revenue was up 84.1% compared to the same quarter last year. On average, equities research analysts expect that Aralez Pharmaceuticals Inc. will post ($1.00) earnings per share for the current fiscal year.

In other news, insider Eric Trachtenberg acquired 10,000 shares of Aralez Pharmaceuticals stock in a transaction dated Monday, May 16th. The stock was bought at an average cost of $3.76 per share, with a total value of $37,600.00. Following the completion of the transaction, the insider now directly owns 144,500 shares of the company’s stock, valued at $543,320. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Andrew I. Koven acquired 71,500 shares of Aralez Pharmaceuticals stock in a transaction dated Thursday, May 12th. The shares were purchased at an average cost of $3.49 per share, with a total value of $249,535.00. Following the completion of the transaction, the insider now directly owns 1,610,306 shares of the company’s stock, valued at $5,619,967.94. The disclosure for this purchase can be found here.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.